NCT04503863View on ClinicalTrials.gov

An Additional Study of NPC-22 in Healthy Adult Males

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

November 6, 2020

Study Completion Date

December 28, 2021

Conditions
Safety and Pharmacokinetics
Interventions
DRUG

NPC-22

Single administration of middle dose NPC-22

DRUG

NPC-22

Single administration of high dose NPC-22

DRUG

NPC-22 Placebo

Single administration of NPC-22 Placebo

Trial Locations (1)

160-0017

Medical Corporation Shinanokai Shinanozaka Clinic, Shinjuku-Ku

Sponsors

Lead Sponsor

Nobelpharma
All Listed Sponsors
lead

Nobelpharma

INDUSTRY

NCT04503863 - An Additional Study of NPC-22 in Healthy Adult Males | Biotech Hunter | Biotech Hunter